Clinical Usefulness of Second-Generation Antipsychotics in Treating Children and Adolescents Diagnosed with Bipolar or Schizophrenic Disorders

Objective: Children and adolescents with a range of psychiatric disorders are increasingly being prescribed atypical or second-generation antipsychotics (SGAs). While SGAs are effective at treating conduct and behavioural symptoms, they infer significant cardiometabolic risk. This study aims to explore what patient, treatment, and health care utilization variables are associated with adherence to Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) metabolic monitoring guidelines. Method: A retrospective chart review of 294 children and adolescents accessing a large outpatient psychiatry setting within a 2-year study period (2014-2016) was conducted. Baseline and follow-up metabolic monitoring, demographic, treatment, and health care utilization variables were then assessed over a 1-year period of interest. Results: Metabolic monitoring practices did not adhere to CAMESA guidelines and were very poor over the 1-year observation period. There were significant differences between children (ages 4-12 years, n = 99) and adolescents (ages 13-18 years, n = 195). In adolescents, factors associated with any baseline metabolic monitoring were a higher number of psychiatry visits (odds ratio [OR], 1.2; 95% confidence interval [CI], 1.10 to 1.41), longer duration of contact (OR, 14; 95% CI, 2.31 to 82.4), and use of other non-SGA medications (OR, 3.2; 95% CI, 1.17 to 8.94). Among children, having an emergency room visit (OR, 3.4; 95% CI, 1.01 to 11.71) and taking aripiprazole (OR, 7.4; 95% CI, 2.02 to 27.45) increased the odds of receiving baseline metabolic monitoring. Conclusion: Findings from this study highlight the need for better metabolic monitoring for children and adolescents taking SGAs. Enhanced focus on opportunities for multidisciplinary collaboration is needed to improve the quality of care offered to this population.

Download Full-text

Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents

Journal of Clinical Psychopharmacology ◽

10.1097/jcp.0b013e3182549259 ◽

2012 ◽

Vol 32 (3) ◽

pp. 309-316 ◽

Cited By ~ 112

Author(s):

David Cohen ◽

Olivier Bonnot ◽

Nicolas Bodeau ◽

Angèle Consoli ◽

Claudine Laurent

Keyword(s):

Adverse Effects ◽

Children And Adolescents ◽

Second Generation ◽

Second Generation Antipsychotics

Download Full-text

Using marginal structural models to identify the cardiovascular adverse effects of second generation antipsychotics in children and adolescents

Journal of Epidemiological Research ◽

10.5430/jer.v1n1p5 ◽

2015 ◽

Vol 1 (1) ◽

pp. 5

Author(s):

Avnish Tripathi ◽

George B. Black ◽

Jeanette M. Jerrell

Keyword(s):

South Carolina ◽

Children And Adolescents ◽

Selective Serotonin Reuptake Inhibitors ◽

Second Generation ◽

Structural Models ◽

Marginal Structural Models ◽

Data Set ◽

Pharmacy Claims ◽

Increased Risk ◽

Second Generation Antipsychotics

In pediatric patients, we examined the association between exposure to five second generation antipsychotics (SGAs) and incidentcardiovascular events (arrhythmic or ischemic/myocardial) over time using marginal structural models (MSM), while controllingfor salient comorbid conditions and co-prescribed psychotropic medications. A retrospective cohort, longitudinal/ observationalstudy design was used to evaluate Medicaid medical and pharmacy claims in 4140 children and adolescents prescribed SGAsfrom South Carolina USA’s Medicaid program covering outpatient and inpatient medical services and medication prescriptionsbetween January, 1996 and December, 2005. Exposure to multiple SGAs (Risk Ratio [RR]=2.37; 95% CI=1.17-4.83), coprescribedpsychostimulants (RR=1.37; CI=1.03-1.81), and comorbid hypertension (RR=2.23; CI=1.28-3.89) were associatedwith a significantly increased risk of arrhythmias compared to those not exposed, whereas exposure to co-prescribed serotoninnorepinephrine reuptake inhibitor/heterocyclic compounds was associated with a significantly decreased risk of arrhythmias(RR=0.59; CI=0.35-0.99). The risk of incident ischemic/myocardial events was significantly associated with the co-prescription ofmood stabilizers (RR=1.68; CI=1.06-2.68) or selective serotonin reuptake inhibitors (RR=1.91; CI=1.18-3.09), and the presenceof comorbid hypertension (RR=3.97; CI=1.96-8.07) and obesity (RR=2.21; CI=1.34-3.67). MSM analyses comparing multipletreatments while controlling for confounding variables in an observational, longitudinal data set provide important, differentialestimates of outcome, when randomized, controlled trials estimating low-incidence outcomes such as cardiovascular adverseevents in large pediatric patient populations are not feasible.

Download Full-text